Chinook Therapeutics and Ionis Pharmaceuticals have entered a partnership to develop an antisense oligonucleotide (ASO) therapy to treat a rare, severe chronic kidney disease.

The collaboration aims to discover, develop and commercialise an ASO therapy.

It will use the precision medicine approach, as well as the deep expertise of Chinook Therapeutics in nephrology and knowledge of Ionis Pharmaceuticals in RNA-targeted therapeutics.

Antisense therapies are designed for destroying mRNA, reducing the amount of disease-causing protein.

They will also have the potential to treat diseases that are caused by too little protein by increasing production, thus restoring the protein to normal levels.

Ionis Pharmaceuticals will receive an undisclosed upfront payment from Chinook Therapeutics under the collaboration.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company will also be entitled to receive potential development and regulatory milestone payments, along with royalty payments.

It will also handle the IND-enabling toxicology studies while Chinook Therapeutics will undertake the clinical development and commercialisation activities of the therapy.

Chinook Therapeutics chief scientific officer Andrew King said: “We are pleased to collaborate with Ionis on this preclinical discovery programme as we continue to strengthen Chinook’s position as the leading kidney disease company.

“Developing an ASO therapy enhances our ability to target key genetic and molecular drivers and expands our precision medicine pipeline for rare severe chronic kidney diseases while continuing to pursue our goal of making dialysis and transplant unnecessary for people living with kidney disease.”